USClinicalTrials.govClinical trialPhase 1Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
Official record
- Identifier
NCT07593092- Recruiting locations
country
United States- Interventions studied
- XmAb541XmAb808
- Lead sponsor
- Xencor, Inc.
- Target enrolment
- 90 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Status
- Recruiting
- First posted
- May 18, 2026
- Last updated on the registry
- Aug 13, 2026
- Age
- 18 Years
- Sex
- FEMALE
- Study contact
- The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria: * Age ≥ 18 years. * CLDN6+ tumor * Histological or cytological documentation of locally advanced, recurrent, or metastatic high grade serous ovarian carcinoma (HGSOC) including fallopian tube or primary peritoneal origin * Adequate Eastern Cooperative Oncology Group performance status * Life expectancy ≥ 3 months * Adequate organ function Exclusion Criteria: * Prior exposure to a CLDN6 targeting immune cell engager * Patients with treated brain metastases may participate, provided they are radiologically stable. * Active known or suspected autoimmune disease * Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug * Clinically significant cardiovascular, pulmonary or gastrointestinal disease * Active viral hepatitis B or hepatitis C
- Indexed under
- Ovarian Cancer